-
1 Comment
Jinyu Bio-technology Co., Ltd is currently in a long term downtrend where the price is trading 17.0% below its 200 day moving average.
From a valuation standpoint, the stock is 60.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
Jinyu Bio-technology Co., Ltd's total revenue rose by 43.6% to $483M since the same quarter in the previous year.
Its net income has increased by 44.4% to $113M since the same quarter in the previous year.
Finally, its free cash flow grew by 1691.8% to $218M since the same quarter in the previous year.
Based on the above factors, Jinyu Bio-technology Co., Ltd gets an overall score of 3/5.
| Industry | Biotechnology |
|---|---|
| Exchange | SHG |
| CurrencyCode | CNY |
| ISIN | CNE000000Y37 |
| Sector | Healthcare |
| Beta | 0.71 |
|---|---|
| Market Cap | 8B |
| PE Ratio | 101.14 |
| Target Price | 7.18 |
| Dividend Yield | None |
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary products in China. Its product portfolio includes Jinyu Baoling, Yangzhou Youbang, and Liaoning Yikang animal vaccines for the prevention of foot, porcine, mycoplasma pneumoniae, porcine reproductive and respiratory syndrome, porcine pseudorabies, pathogenic avian influenza, brucellosis bacterial disease, bovine viral diarrhea and mucosal, infectious rhinotracheitis, and other domestic animal diseases. The company was founded in 1992 and is headquartered in Hohhot, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600201.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
